Compare Ginkgo Bioworks Holdings Inc (DNA) vs SkyWest Inc (SKYW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs SkyWest Inc — how do they compare? Ginkgo Bioworks Holdings Inc trades at $13 (market cap $763.64M), while SkyWest Inc trades at $96.52 (market cap $3.75B). The key difference: SkyWest Inc is far larger — about 4.9× Ginkgo Bioworks Holdings Inc's market cap, and Ginkgo Bioworks Holdings Inc is trading nearer its 52-week high, SkyWest Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Ginkgo Bioworks Holdings Inc for 7 Days and SkyWest Inc for 8 Days on average.
| DNA | SKYW | |
|---|---|---|
Market Cap | $763.64M | $3.75B |
Volume | 3,204,177 | 196,324 |
Sector | Health | Industrials |
52-Week High | $15.83 | $115.94 |
52-Week Low | $5.48 | $78.40 |
Typical Hold Time | 7 Days | 8 Days |
Enterprise Value | $865.59M | $5.54B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $11.34, down 1.13% on the day, with a bullish technical signal from moving averages. The company reported a net loss of $312.76 million on $170.16 million revenue for 2025, with negative cash flow. Recent news includes a $17.5 million ARPA-H subcontract for RNA medicine manufacturing, highlighting ongoing strategic initiatives despite financial challenges.
The outlook remains speculative given persistent losses and cash burn, though analyst consensus is divided. Key risks include execution on revenue growth and path to profitability. Upside depends on successful commercialization of its biotech platform and partnerships, but high volatility and fundamental weakness warrant caution for investors.
SkyWest (SKYW) trades at $96.73, up 0.09% on the day, with a bearish technical signal but strong fundamentals including a P/E of 9.6 and net income margin of 9.78%. Recent earnings show mixed results, with a Q1 2026 beat but a Q2 2026 miss. The company is expanding its fleet and flying agreements, supporting growth amid cost pressures.
The outlook is cautiously optimistic, with a consensus price target of $112 offering 16% upside. Risks include execution on cost control and competitive pressures, but low valuation and analyst buy ratings suggest potential for recovery if operational trends improve.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About SkyWest Inc
SkyWest, Inc. is a major North American regional airline company, operating primarily through its subsidiary, SkyWest Airlines. The company provides regional airline service to various large airlines under contract, including United Airlines (as United Express), Delta Air Lines (as Delta Connection), American Airlines (as American Eagle), and Alaska Airlines (as Alaska SkyWest). SKYW's primary business is providing essential flight services, connecting smaller cities to major airline hubs across the United States.
Read more on SKYW →
